Skip to main content
Testing version — LOERadar is in active testing. Features and data may change.
LOERadar
LOE
Radar
Hub
News
Changes
Search
Log in
Get Started
VIZAMYL (FLUTEMETAMOL F-18) | LOERadar
Viewing data from:
Latest
2026-07-01
2026-06-01
2026-05-01
2026-04-01
2026-03-28
2026-02-17
2026-02-10
2025-12-14
2025-02-26
2025-01-25
2024-11-08
2023-07-23
2023-06-15
2023-05-13
2023-01-26
2022-11-22
2022-10-28
2022-09-29
2022-07-09
2022-06-29
2022-04-08
2022-03-09
2021-12-28
2021-05-05
2021-03-12
2020-12-22
2020-11-12
2019-12-14
2019-09-15
VIZAMYL
NDA
Get alerts
FLUTEMETAMOL F-18 | N203137 | GE HEALTHCARE
2 strengths
1 unique patent
0 unique exclusivities
Patents
SEC Intel
Revenue
PTAB
Reexams
Litigation
Petitions
Trials
Approvals
Label
Products
Patent Timeline
1 unique patent by expiration date
All strengths
40.5mCi/10ML (4.05mCi/ML)
121.5mCi/30ML (4.05mCi/ML)
Active (1)
Today
2027
2028
Today
8916131
Sep. 16, 2028
PTAB Proceedings
No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board
Hatch-Waxman Litigation
No ANDA patent litigation cases (NOS 835) matched from PACER
Citizen Petitions
No FDA citizen petitions matched from Regulations.gov
Products (2)
Sort:
Name
↑
Applicant
Strength
Approval
#001 — 40.5mCi/10ML (4.05mCi/ML)
RLD
1 patent
0 exclusivities
▴
INJECTABLE;INTRAVENOUS | Approved: Oct 25, 2013
Patents (1)
Patent #
Expiration
PED
Drug Substance
Drug Product
Use Code
Delist
8916131
Sep 16, 2028
—
—
Yes
—
—
#002 — 121.5mCi/30ML (4.05mCi/ML)
RLD
1 patent
0 exclusivities
▾
INJECTABLE;INTRAVENOUS | Approved: Oct 25, 2013